Frontline chemotherapy with bortezomib-containing combinations improves response rate and survival in primary plasma cell leukemia: a retrospective study from GIMEMA Multiple Myeloma Working Party

Livio Pagano, Giovanna Rosaria Mansueto, Antonella Venditti, Ferdinando Ferrara, G D'Arena, Cg Valentini, G Pietrantuono, R Guariglia, Mc Martorelli, O Villani, D Onofrillo, A Falcone, G Specchia, G Semenzato, N Di Renzo, L Mastrullo, A Palumbo, P. Musto

Research output: Contribution to journalArticle

62 Citations (Scopus)

Abstract

The best therapeutic approach for primary plasma cell leukemia (PPCL) remains unknown so far. In very limited studies, the poor clinical outcome of this aggressive variant of multiple myeloma seemed to be ameliorated by the use of the proteasome inhibitor bortezomib. Aiming to provide more consolidated data, this multicenter retrospective survey focused on unselected and previously untreated PPCL patients who had received bortezomib as frontline therapy.
Original languageEnglish
Pages (from-to)1499-1502
Number of pages4
JournalAnnals of Oncology
Volume23
DOIs
Publication statusPublished - 2012

Keywords

  • plasmacell leukemia

Fingerprint

Dive into the research topics of 'Frontline chemotherapy with bortezomib-containing combinations improves response rate and survival in primary plasma cell leukemia: a retrospective study from GIMEMA Multiple Myeloma Working Party'. Together they form a unique fingerprint.

Cite this